PET/MRI imaging in neuroendocrine neoplasm
- PMID: 36525051
- DOI: 10.1007/s00261-022-03757-1
PET/MRI imaging in neuroendocrine neoplasm
Abstract
Molecular imaging plays a vital role in the management of neuroendocrine neoplasms (NENs). Somatostatin receptor (SSTR) PET is critical for evaluating NENs, ascertaining peptide receptor radionuclide therapy (PRRT) eligibility, and treatment response. SSTR-PET/MRI can provide a one-stop-shop multiparametric evaluation of NENs. The acquisition of complementary imaging information in PET/MRI has distinct advantages over PET/CT and MR imaging acquisitions. The purpose of this manuscript is to provide a comprehensive overview of PET/MRI and a current review of recent PET/MRI advances in the diagnosis, staging, treatment, and surveillance of NENs.
Keywords: Neuroendocrine neoplasm; PET/CT; PET/MRI; PPRT; SSTR.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
PET/CT and PET/MRI in neuroendocrine neoplasms.Abdom Radiol (NY). 2022 Dec;47(12):4058-4072. doi: 10.1007/s00261-022-03516-2. Epub 2022 Apr 15. Abdom Radiol (NY). 2022. PMID: 35426497 Review.
-
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.J Nucl Med. 2020 Nov;61(11):1560-1569. doi: 10.2967/jnumed.119.241414. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169914
-
Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.J Nucl Cardiol. 2023 Dec;30(6):2676-2691. doi: 10.1007/s12350-023-03345-w. Epub 2023 Aug 16. J Nucl Cardiol. 2023. PMID: 37587328 Free PMC article.
-
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.J Nucl Med. 2019 Mar;60(3):377-385. doi: 10.2967/jnumed.118.215848. Epub 2018 Aug 16. J Nucl Med. 2019. PMID: 30115686
-
Neuroendocrine Tumors: Diagnostics.PET Clin. 2024 Jul;19(3):325-339. doi: 10.1016/j.cpet.2024.03.008. Epub 2024 May 6. PET Clin. 2024. PMID: 38714399 Review.
Cited by
-
PET/MRI: pictorial review of hepatobiliary and pancreatic applications.Abdom Radiol (NY). 2025 Feb;50(2):875-901. doi: 10.1007/s00261-024-04548-6. Epub 2024 Sep 10. Abdom Radiol (NY). 2025. PMID: 39254711 Review.
-
Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI.Ther Adv Med Oncol. 2023 Oct 24;15:17588359231189133. doi: 10.1177/17588359231189133. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37885461 Free PMC article.
-
Advances in Molecular Imaging for Neuroendocrine Neoplasms.Cancers (Basel). 2025 Jun 17;17(12):2013. doi: 10.3390/cancers17122013. Cancers (Basel). 2025. PMID: 40563663 Free PMC article. Review.
-
PET/MRI for evaluation of patients with pancreatic cancer.Abdom Radiol (NY). 2023 Dec;48(12):3601-3609. doi: 10.1007/s00261-023-03943-9. Epub 2023 May 16. Abdom Radiol (NY). 2023. PMID: 37191756 Review.
References
-
- Rajamohan, N., et al., PET/CT and PET/MRI in neuroendocrine neoplasms. Abdom Radiol (NY), 2022.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources